Breyanzi CAR T-cell Therapy Gets Positive CHMP Opinion for RRLBCL

Manali Kamdar, MD from University of Colorado

Bristol Myers Squibb has received a positive opinion from the European Medicines Agency’s CHMP for their CAR T cell therapy, Breyanzi (lisocabtagene maraleucel), as a treatment option for patients with relapsed or refractory large B-cell lymphoma who have undergone one prior therapy.

Breyanzi, CAR T-cell therapy, positive CHMP opinion, R/R large B-cell lymphoma, Manali Kamdar, MD, University of Colorado, European Medicines Agency, chimeric antigen receptors, CD19 cells, TRANSFORM study, autotransplant, salvage chemotherapy, event-free survival, progression-free survival, overall response rate, complete response rate